 During the open label trial, 57.1 of roflumilast-treated participants achieved Investigator Global Assessment IGA of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months 40.1 weeks Efficacy was consistent over time across all endpoints, and no lessening of response no tachyphylaxis from roflumilast cream ... The post Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumil... 